Brief: Mayne Pharma Posts H1 Gross Margin 53%
26/02/2025 01:30
Feb 26 (Reuters) - Mayne Pharma Group Ltd MYX.AX: H1 GROSS MARGIN 53% H1 REVENUE AUD 94.3 MILLION H1 GROSS PROFIT AUD 76.9 MILLION H1 ADJUSTED EBITDA AUD 31 MILLION COMPANY EXPECTS TO GROW UNDERLYING EBITDA IN 2HFY25 VIA REVENUE GROWTH Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)